

Special Issue

Immune Response of People Living with HIV to COVID-19

Message from the Guest Editors

For people living with HIV (PLWH) who experience SARS-CoV-2, limited evidence suggests a lower magnitude of humoral and cell-mediated immune responses and a shorter-duration antibody response compared to HIV-naïve individuals. Moreover, further study is needed to elucidate the immune response following vaccination among the PLWH population, since sparse data exist on the immunogenicity of non-replicating adenovirus vector, messenger RNA, or protein-based COVID-19 vaccines in PLWH. Suboptimal responses to immunization against other infections such as yellow fever, hepatitis B, influenza, polio, diphtheria, and tetanus among PLWH were also reported. The focus of this Special Issue is on recent advances in the understanding of the host immune responses following natural infection and vaccination, as well as the immunologic processes resulting in post-acute sequelae of SARS-CoV-2 infection among PLWH. Adding new information on this population is expected to improve our knowledge of the immune response towards SARS-CoV-2 among PLWH and aid in tailored prevention and treatment modalities against COVID-19.

Guest Editors

Dr. Lemonia Skoura
Dr. Helena C. Maltezou
Dr. Giota Lourida

Deadline for manuscript submissions

closed (30 November 2022)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/124390

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition and Behavior, University College
Roosevelt, 4331 CB Middelburg, The Netherlands

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).